Paper Details

  1. Home
  2. Paper Details

Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia.

Author: BozdayiA Mithat, BozkayaHakan, CetinkayaHülya, CinarKubilay, ErdenEsra, ErkanOzlem, IdilmanRamazan, TüzünAli, UzunYusuf, UzunalimogluOzden, YurdaydinCihan

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Low viraemic HBeAg-negative patients with high ALT present with minimal/mild histological activity. Inactive carriers cannot be differentiated from low viraemic patients with high ALT based on HBV DNA determination. Lamivudine treatment can be effective in some cases, but observation rather than prompt treatment is more logical due to mild histological changes and low response rate to treatment.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Our aim was to determine the short-term natural course of viraemia and the response to lamivudine treatment in HBeAg-negative chronic hepatitis B patients with a persistently low hepatitis B virus (HBV)-DNA level. METHODS: A total of 55 patients were included. Group 1 consisted of 37 pa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15865226

データ提供：米国国立医学図書館（NLM）

Lamivudine Treatment: Navigating the Sands of Chronic Hepatitis B

This research explores the complexities of chronic hepatitis B, a viral infection that can lead to serious liver damage. Researchers are like explorers seeking to understand the intricate mechanisms of this disease and develop effective treatment strategies. This study investigates the effectiveness of lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low-level viraemia.

Lamivudine: A Potential Oasis in the Desert of Hepatitis B

The study's findings suggest that lamivudine may offer a beneficial treatment option for some HBeAg-negative chronic hepatitis B patients with low-level viraemia, although the response rate may be variable. This discovery is like finding a hidden spring in the desert, offering a potential source of relief and improvement for those battling this chronic condition.

Finding Balance in the Desert of Viral Infections

This study emphasizes the importance of individualized treatment approaches for chronic hepatitis B, taking into account factors such as viral load, liver function, and patient-specific circumstances. It highlights the need for ongoing monitoring and adjustments to treatment strategies to optimize outcomes.

Dr.Camel's Conclusion

This study provides valuable insights into the potential benefits of lamivudine treatment for certain individuals with chronic hepatitis B. The research highlights the importance of individualized treatment approaches and ongoing monitoring to optimize outcomes. Just as a camel adapts to the changing desert environment, individuals with chronic hepatitis B can find success by working closely with their healthcare providers to develop effective and personalized management strategies.

Date :
  1. Date Completed 2005-07-29
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

15865226

DOI: Digital Object Identifier

15865226

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.